
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva is well-positioned in the competitive biopharmaceutical industry with a strong research and development team focused on developing innovative treatments for MASH, a growing health concern globally. With a diversified pipeline and a solid financial standing, particularly in comparison to other smaller biotech companies, Inventiva has the potential to bring highly valuable therapies to patients and generate significant returns for investors. Additionally, the promising results of their lead drug candidate, lanifibranor, in phase 2 trials for MASH treatment show strong potential for market success and further expansion into other related disease areas.
Bears say
Inventiva is currently operating in a highly competitive market with several other companies also developing drugs for MASH. The company's lanifibranor has shown some promising data in Phase 2 and 3 trials, but it will face challenges in differentiating itself from competitors and gaining market share. Additionally, the need for ongoing capital raises to fund clinical trials and commercialization poses a significant risk for the company's financial stability.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares